Leveraging biosimilars to drive savings and support patient access

By the end of 2024, 3 FDA-approved biosimilars to Stelara for patients living with inflammatory conditions will be closer to launch, enabling lower total drug spend.

July 01, 24

Transforming oncology care through a holistic, patient-centric, and consultative approach

Evernorth Health Services has introduced Evernorth Oncology Benefit Services, which will be available to eligible commercial plan sponsors in 2025, with plans to expand over time.

June 10, 24

Evernorth chief bullish on driving affordability through biosimilars and access through guided care

May 08, 24

Outcomes 2024: How Evernorth manages the drug pipeline today and prepares for tomorrow

May 08, 24

How Accredo specialty pharmacy provides personalized care to patients living with specialty conditions

A behind-the-scenes look at how our team of specialists provides high-touch, personalized care to patients facing chronic and complex specialty conditions.

May 02, 24

Keeping member health on track: A snapshot of the PBM’s clinical expertise

Express Scripts is helping patients understand and manage their conditions through comprehensive disease management.

April 19, 24